November 13, 2020
5,585
89
1.59%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
31:13Now PlayingGenentech, the American biotechnology company, began trials in March to see if one of its existing medicines could be used to combat COVID-19 as it spread across the U.S. causing hospital overruns and thousands of deaths with a special effort to enroll diverse groups disproportionately impacted by the virus. While setting up these trials, the company changed ways of working to virtually meet the needs of patients who found themselves without access to their medicines and partnered with others to fight the pandemic.
Genentech CEO Alexander Hardy believes they’re learning a great deal that they will carry forward to better serve patients in the future. Join Washington Post columnist David Ignatius for a one-on-one conversation with Alexander Hardy on Friday, Nov. 13 at 1:00 p.m. ET.
Washington Post Live is the newsroom’s live journalism platform, featuring interviews with toplevel government officials, business leaders, cultural influencers and emerging voices on the most pressing issues driving the news cycle nationally and across the globe. From oneonone, newsmaker interviews to indepth multisegment programs, Washington Post Live brings The Post’s newsroom to life on stage. Subscribe to The Washington Post on YouTube
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.